1 / 8

Flow of Patients Through Trial

Flow of Patients Through Trial. Nissen SE, et al. JAMA 2008;299:1547-60. Baseline Characteristics of the Study Population (n=839) a. Nissen SE, et al. JAMA 2008;299:1547-60. Body Weight, Waist Circumference, Metabolic Outcomes, and Blood Pressure in Patients Completing the Trial (n=676) a.

ringo
Download Presentation

Flow of Patients Through Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Flow of Patients Through Trial Nissen SE, et al. JAMA 2008;299:1547-60

  2. Baseline Characteristics of the Study Population (n=839)a Nissen SE, et al. JAMA 2008;299:1547-60

  3. Body Weight, Waist Circumference, Metabolic Outcomes, and Blood Pressure in Patients Completing the Trial (n=676)a Nissen SE, et al. JAMA 2008;299:1547-60

  4. Effects of Rimonabant on Body Weight, Waist Circumference, and Levels of HDL-C, Triglycerides, Fasting Insulin, and Glycated Hemoglobin (HbA1c) Nissen SE, et al. JAMA 2008;299:1547-60

  5. Baseline, Follow-up, and Change from Baseline in Intravascular Ultrasound End Points in Patients Completing the Trial (n = 676) Nissen SE, et al. JAMA 2008;299:1547-60

  6. Primary Efficacy Parameter (Percent Atheroma Volume) in Subgroups Nissen SE, et al. JAMA 2008;299:1547-60

  7. Major Cardiovascular Adverse Events, Treatment-Emergent Adverse Events, and Reasons for Study Drug Discontinuation (Randomized Population, n=839) Nissen SE, et al. JAMA 2008;299:1547-60

  8. Cumulative Incidence of Drug Discontinuation Nissen SE, et al. JAMA 2008;299:1547-60

More Related